Education
About Us
Working with TipRanks
Follow Us
Intensity Therapeutics, Inc. (INTS)
NASDAQ:INTS
INTS Stock Chart & Stats
$0.47
-$0.05(-2.51%)
At close: 4:00 PM EST
$0.47
-$0.05(-2.51%)
Day’s Range― - ―
52-Week Range$0.19 - $3.17
Previous CloseN/A
Volume52.56K
Average Volume (3M)5.11M
Market Cap
$26.24M
Enterprise Value$3.70M
Total Cash (Recent Filing)$7.07M
Total Debt (Recent Filing)$118.00K
Price to Earnings (P/E)―
Beta0.19
Next Earnings
Mar 12, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding49,055,460
10 Day Avg. Volume8,790,984
30 Day Avg. Volume5,112,980
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)8.39
Price to Sales (P/S)0.00
P/FCF Ratio-1.61
Enterprise Value/Market Cap0.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.40
Forecast
1Y Price Target
$3.33Price Target Upside608.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressIntensity Therapeutics has initiated a Phase 3 study with INT230-6 in sarcoma patients.
Clinical Trial SuccessThe drug INT230-6 achieved a median overall survival of 11.9 months, which is meaningfully above the historical median overall survival of 4-7 months in similar Phase 1/2 trials.
Financial StabilityManagement expects to fund operations until the end of 1Q27, following a cash raise of $5.7M in October.
Bears Say
Financial PerformanceIntensity reported no revenues and a net loss of $0.06 per diluted share for 3Q25, and projects no revenues with a net loss of $0.36 per diluted share for 2025.
Operational ChallengesThe company paused new patient enrollment in the ongoing Phase 2 study, INVINCIBLE-4, due to some patients experiencing localized skin irritation near the tumor site.
Intensity Therapeutics, Inc. News
INTS FAQ
What was Intensity Therapeutics, Inc.’s price range in the past 12 months?
Intensity Therapeutics, Inc. lowest stock price was $0.18 and its highest was $3.17 in the past 12 months.
What is Intensity Therapeutics, Inc.’s market cap?
Intensity Therapeutics, Inc.’s market cap is $26.24M.
When is Intensity Therapeutics, Inc.’s upcoming earnings report date?
Intensity Therapeutics, Inc.’s upcoming earnings report date is Mar 12, 2026 which is in 88 days.
How were Intensity Therapeutics, Inc.’s earnings last quarter?
Intensity Therapeutics, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.063 by $0.003.
Is Intensity Therapeutics, Inc. overvalued?
According to Wall Street analysts Intensity Therapeutics, Inc.’s price is currently Undervalued.
Does Intensity Therapeutics, Inc. pay dividends?
Intensity Therapeutics, Inc. does not currently pay dividends.
What is Intensity Therapeutics, Inc.’s EPS estimate?
Intensity Therapeutics, Inc.’s EPS estimate is -0.05.
How many shares outstanding does Intensity Therapeutics, Inc. have?
Intensity Therapeutics, Inc. has 49,055,460 shares outstanding.
What happened to Intensity Therapeutics, Inc.’s price movement after its last earnings report?
Intensity Therapeutics, Inc. reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.063. Following the earnings report the stock price went down -4.167%.
Which hedge fund is a major shareholder of Intensity Therapeutics, Inc.?
Currently, no hedge funds are holding shares in INTS
Intensity Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.33 (608.51% Upside)
$3.33 (608.51% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-91.87%
12-Months-Change
Fundamentals
Return on Equity
-334.12%
Trailing 12-Months
Asset Growth
-48.77%
Trailing 12-Months
Company Description
Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
INTS Stock 12 Month Forecast
Average Price Target
$3.33
▲(608.51% Upside)
Technical Analysis
Biodexa Pharmaceuticals
―
Q/C Technologies
―
Salarius Pharmaceuticals
―
Scinai Immunotherapeutics
―
Oragenics
―
Ownership Overview
0.15% Insiders
0.18% Mutual Funds
3.41% Other Institutional Investors
96.21% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---